Disparities in uptake of 13-valent pneumococcal conjugate vaccine among older adults in the United States
| Autor: | John M. McLaughlin, David L. Swerdlow, Farid Khan, Oliver Will, Aaron Curry, Vincenza Snow, Raul E. Isturiz, Luis Jodar |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: | |
| Zdroj: | Human Vaccines & Immunotherapeutics, Vol 15, Iss 4, Pp 841-849 (2019) |
| Druh dokumentu: | article |
| ISSN: | 2164-5515 2164-554X 21645515 |
| DOI: | 10.1080/21645515.2018.1564434 |
| Popis: | Background: In September 2014, 13-valent pneumococcal conjugate vaccine (PCV13) was universally recommended for all US adults aged ≥65 years. Adult PCV13 coverage, including whether disparities in uptake exist, however, is not well-described. Methods: We used a monthly series of cross-sectional analyses of administrative medical and prescription claims data collected by IQVIA and linked to sociodemographic data collected by Experian to estimate overall and subpopulation-level uptake of PCV13 among US adults aged ≥65 years. Results: Among adults aged ≥65 years, 43.3% received PCV13 by the end of November 2017. Race/ethnicity, annual household income, education status, and neighborhood urbanicity were strongly related to PCV13 uptake among adults aged ≥65 years. Lower uptake of PCV13 was observed for non-Hispanic black (36.3%) and Hispanic (30.0%) adults (vs 45.6% for non-Hispanic whites, P |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|